Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the rate of progression free survival of patients
with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are
treated with combination chemotherapy supplemented by biological agents panitumumab or
bevacizumab.